Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review

Clinical and Translational Medicine

Table 2 The resistant mutations and sensitive mutations of ALK inhibitors

ALK-TKI	Sensitive mutations	Insensitive mutations	References
Cizotinib	L1198F	1151Tins, L1152P, L1152R, C1156Y, I1171T, F1174C, F1174L, F1174V, L1196M, G1202R, S1206, G1269, G1269S, R1275Q	[21,22,23,24]
Ceritinib	I1171T, L1196M, S1206Y, G1269A, F1174L, V1180L	C1156Y, 1151Tins, L1152R, F1174C, G1202R, G1123S	[25,26,27,28]
Alectinib	1151Tins, L1152R, C1156Y, F1174L, F1174V, L1196M, S1206Y, G1269A, R1275Q	I1171T, I1171S, V1180L, G1202R	[28,29,30,31,32]
Lorlatinib	F1147L, 1151Tins, L1152R, C1156Y, L1192R, L1196M, G1202R, S12026Y, G1269A	L1198F	[22, 33,34,35]